Company Analysis
Sign in

Innate Pharma S.A. (IPHA)

Nasdaq: IPHA · Biological Products, (No Diagnostic Substances) · Marseille · filing with the SEC since 2014
Full chart Alerts Compare
Grade4.3
◀ Past 5.9● Present 4.0▶ Future 3.5
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue€9.0M-55.2%
Net income-€49.2M+0.6%
Earnings per share€-0.55+9.8%
Operating cash flow-€52.8M-665.0%
Cash€28.1M-57.7%
Debtn/a
Shareholders’ equity-€21.7M-345.7%
Shares, diluted89.6M+10.5%
Return on equityn/a
The recordfrom its filings
Filings in 202636
Newest filingNov 12 · 6-K
Annual reportApr 1, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted94
Filer categoryAccelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
171819202122232425
As filed, in EUR. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton IPHA · research, not advice